Delivering better treatments
Camurus is committed to improving the lives of patients
with severe and chronic diseases
updates
Latest news
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2025/2028
Resolutions at the annual general meeting 2025 in Camurus
Disease areas
Focus on severe and chronic diseases
Developing treatments for diseases within the central nervous system, rare diseases, endocrinology, oncology and supportive care.
Events
Upcoming events
-
16 Jun
BIO International Convention 2025
Camurus will participate in this conference in Boston, MA, US, 16-19 June, 2025.
-
26 Jun
ABG Sundal Collier Spotlight Conference
Camurus’ Chief Business Development Officer Fredrik Joabsson is presenting at this conference in Frankfurt, 26 June. The presentation can be seen by the conference participants. More information will follow closer to the event.
-
17 Jul
Interim Report January-June 2025
The interim report January-June is published on 17 July 2025.
Latest financial report
Camurus’ Interim Report January-March 2025
15 May 2025
Annual General Meeting
Camurus’ Annual General Meeting 2025 was held on Tuesday, 27 May in Lund, Sweden.
Resolutions at the Annual General Meeting 2025 in Camurus
See documents for Annual General Meeting 2025
See more information on Camurus’ general meetings
See archive general meetings
Pipeline
Diversified pipeline with large potential
Camurus’ innovative product candidates are designed to address important unmet medical needs, with the potential to make significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.
sustainability
Sustainable solutions for a healthier world
Ensuring the long-term successful development of our business – for the benefit of patients, healthcare systems, employees and shareholders.
